We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
We’re excited to share that Amgen has selected West’s Daikyo Crystal Zenith® vials with FluroTec® stoppers to contain its FDA-approved therapy IMLYGIC™ (talimogene laherparepvec).
We’re excited to share that Amgen has selected West’s Daikyo Crystal Zenith® vials with FluroTec® stoppers to contain its FDA-approved therapy IMLYGIC™ (talimogene laherparepvec).
There is growing demand in the biopharmaceutical industry for advanced drug containment systems for sophisticated biologics. Manufactured from a novel cyclic olefin polymer, Crystal Zenith vials offer a break-resistant, high-performance alternative to glass that is designed to meet the complex needs of next-generation therapeutics.
Many new biologics require cold storage environments. While glass has traditionally been used to store and deliver many injectable drugs, it can be unstable in cold and cryogenic storage conditions and poses a risk of breakage with thawing. Our Daikyo Crystal Zenith vials are designed to stand up to ultra-cold and cryogenic environments and help protect the safety and integrity of complex injectable drug products. Additionally, IMLYGIC’s Crystal Zenith container closure system contains FluroTec stoppers, which provide a barrier against extractables and protect against the risk of contamination.
We are proud to work together with Amgen, and all of our biopharmaceutical and pharmaceutical customers, to provide integrated lifecycle solutions that are designed to maintain drug safety, purity and efficacy from development through to commercialization.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Crystal Zenith technology is licensed from Daikyo Seiko, Ltd.
FluroTec® is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
<p>Color has a surprising number of uses in injectables packaging.</p><p>European guidance states that “similarity in packaging which contributes to medication error can be reduced by the judicious use of color on the pack” ¹. Draft guidance issued by the U.S Food and Drug Administration (FDA)² similarly recommends that “sponsors use color prudently to bring attention to the product name, strength, and important warning(s).” Color – when applied thoughtfully and with full awareness of the context in which the drug will be used – can be an important way for manufacturers to help practitioners and patients differentiate products and support their correct use.</p>
The complexity of bringing a combination product, such as an on-body delivery system (OBDS), to market cannot be overstated. Changing or unclear regulations are often cited by the industry as a major source of confusion which contributes to that complexity. However, continuous incorporation of updated standards and newly issued guidance documents during the development process can reduce risk, improve patient safety, save time and headaches when the submission date ultimately approaches.
Philanthropy is a cornerstone of West's culture. It anchors our purpose of standing by the side of our customers to help make a difference in our global community.
Innovation in manufacturing involves a spectrum of evolution improvements resulting in what West’s partner Daikyo Seiko, Ltd. considers "Absolute Quality." Recent continuous improvement efforts helped Daikyo achieve even higher levels in cleanliness of elastomer products.
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” <span>are at the forefront of the patient’s mind as they process their diagnosis and begin treatment</span>. So, how can the patient experience with treatment be supported? By offering the best quality of care.
English
Chinese
